Please use this identifier to cite or link to this item:
Title: A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Austin Authors: Ahn, Thomas;Roberts, Matthew J;Abduljabar, Aous;Joshi, Andre;Perera, Marlon ;Rhee, Handoo;Wood, Simon;Vela, Ian
Affiliation: Department of Urology, Greenslopes Private Hospital, Brisbane, Queensland, Australia
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Urology, Townsville Hospital, Queensland, Australia
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
Department of Urology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
Australian Prostate Cancer Research Center Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia
Centre for Kidney Disease Research, Translational Research Institute, Brisbane, Australia
Issue Date: 2019 2019-01-07
Publication information: Molecular imaging and biology 2019; 21(5): 799-807
Abstract: Metastatic renal cell carcinoma (mRCC) is a disease that portends poor prognosis despite an increasing number of novel systemic treatment options including new targeted therapies and immunotherapy. Ablative intervention directed at oligometastatic RCC has demonstrated survival benefit. Consequently, developing techniques for improved staging of mRCC on contemporary imaging modalities including X-ray computed tomography (CT), magnetic resonance imaging (MRI) and/or bone scan (BS) is a clinical priority. This is relevant for metastatic deposits too small to characterize or lymph nodes within physiological normality. Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein highly expressed on prostate cancer epithelial cells. Recently, small molecules targeting the PSMA receptor, linked to radioactive isotopes have been developed for use with positron emission tomography (PET). Despite its nomenclature, PSMA has also been found to be expressed in the neovasculature of non-prostate cancers such as renal cell carcinoma (RCC) and hence PSMA PET/CT imaging has been proposed as an alternative staging modality. Preliminary small studies involving the use of PSMA PET/CT imaging in mRCC have been encouraging with evidence of improved staging sensitivity which has directly led to change in management in some cases. Given these early encouraging reports, we performed a comprehensive narrative review on the available evidence, including the scientific basis for PSMA expression in RCC, the role of PSMA PET/CT imaging with potential clinical implications in mRCC, its limitations and future opportunities.
DOI: 10.1007/s11307-018-01307-0
ORCID: 0000-0002-2808-9970
PubMed URL: 30617728
Type: Journal Article
Subjects: Gallium
Positron emission tomography
Prostate-specific membrane antigen
Renal cell carcinoma
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.